Answers are grounded in this paper and cite their sources.
Despite great expectations and research efforts, anticancer immunotherapy has not yet become a definitive cure. Perhaps, this is because past reductionist approaches were too simplistic for the patient-specific complex system of co-evolving tumor cells and host immunity. Recent efforts based on a systems-based approach promise improved clinical outcomes engendered by a dynamic modification of personalized therapeutic regimens.
No takes yet. Share an insight, caveat, or question.
Agur et al. (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: